Targeting histone deacetylases for cancer therapy: Trends and challenges

Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and progression. As promising anticancer targets, HDACs have gained a great deal of research interests and two decades of effort has led to the approval of five HDAC inhibitors (HDACis). However, currently traditio...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tao Liang, Fengli Wang, Reham M. Elhassan, Yongmei Cheng, Xiaolei Tang, Wengang Chen, Hao Fang, Xuben Hou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-06-01
Edice:	Acta Pharmaceutica Sinica B
Témata:	HDACs Oncogenesis Selective inhibitor Combination therapy Multitarget agent PROTAC
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2211383523000345
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!